Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer
Journal of the National Comprehensive Cancer Network · 2023
DOI: 10.6004/jnccn.2022.7257 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2023. Verfasst von Kelsey S Lau-Min und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, NHGRI NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Background
Germline genetic testing (GT) for BRCA1/2 is instrumental in identifying patients with breast and ovarian cancers who are eligible for PARP inhibitors (PARPi). Little is known about recent trends and determinants of GT since PARPi were approved for these patients. Patients and Methods: We performed a retrospective cohort study of patients in a nationwide electronic health record (EHR)–derived oncology-specific database with the following GT eligibility criteria: breast cancer diagnosed at age ≤45 years, triple-negative breast cancer diagnosed at age ≤60 years, male breast cancer, or ovarian cancer. GT within 1 year of diagnosis was assessed and stratified by tumor type. Multivariable log-binomial regressions estimated adjusted relative risks (RRs) of GT by patient and tumor characteristics.
Results
Among 2,982 eligible patients with breast cancer, 56.4% underwent GT between January 2011 and March 2020, with a significant increase in GT over time (RR, 1.08; 95% CI, 1.05–1.11, for each year), independent of when PARPi were approved for BRCA1/2 -mutated metastatic breast cancer in January 2018. In multivariable analyses, older age (RR, 0.93; 95% CI, 0.90–0.96, for every 5 years) and Medicare coverage (RR, 0.69; 95% CI, 0.49–0.96 vs commercial insurance) were associated with less GT. Among 5,563 eligible patients with ovarian cancer, 35.4% underwent GT between January 2011 and March 2020, with a significant increase in GT over time (RR, 1.11; 95% CI, 1.07–1.14, for each year) that accelerated after approval of PARPi for BRCA1/2 -mutated, chemotherapy-refractory ovarian cancer in December 2014 (RR, 1.42; 95% CI, 1.19–1.70). Older age (RR, 0.95; 95% CI, 0.93–0.97, for every 5 years) and Black or African American race (RR, 0.80; 95% CI, 0.65–0.98 vs White race) were associated with less GT.
Conclusions
GT remains underutilized nationwide among patients with breast and ovarian cancers. Although GT has increased over time, significant disparities by age, race, and insurance status persist. Additional work is needed to design, implement, and evaluate strategies to ensure that all eligible patients receive GT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts.
- Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
- Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Förderung
- NIEHS NIH HHS
- NHGRI NIH HHS
- NCI NIH HHS
Zitieren
APA
Lau-Min, K. S., McCarthy, A. M., Nathanson, K. L., & Domchek, S. M. (2023). Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2022.7257
Vancouver
Lau-Min KS, McCarthy AM, Nathanson KL, Domchek SM. Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer. Journal of the National Comprehensive Cancer Network. 2023. doi:10.6004/jnccn.2022.7257
BibTeX
@article{LauMin2023,
author = {Lau-Min, Kelsey S and McCarthy, Anne Marie and Nathanson, Katherine L and Domchek, Susan M},
title = {Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2023},
doi = {10.6004/jnccn.2022.7257}
}
EUVIMED